JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 83 filers reported holding JOUNCE THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $60,000 | -96.0% | 12,200 | -95.0% | 0.00% | -94.3% |
| Q1 2019 | $1,514,000 | +60.6% | 244,300 | -12.7% | 0.07% | +7.7% |
| Q4 2018 | $943,000 | -44.2% | 279,900 | +7.7% | 0.06% | -33.0% |
| Q3 2018 | $1,689,000 | +2.2% | 259,857 | +20.5% | 0.10% | 0.0% |
| Q2 2018 | $1,652,000 | +22.5% | 215,700 | +257.1% | 0.10% | +12.8% |
| Q1 2018 | $1,349,000 | -29.7% | 60,400 | -59.9% | 0.09% | -16.5% |
| Q4 2017 | $1,918,000 | -24.1% | 150,500 | -7.2% | 0.10% | -23.7% |
| Q3 2017 | $2,527,000 | +43.8% | 162,200 | +29.4% | 0.14% | +25.0% |
| Q2 2017 | $1,757,000 | +30.6% | 125,300 | +104.7% | 0.11% | +27.1% |
| Q1 2017 | $1,345,000 | – | 61,200 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 10,230,349 | $63,428,000 | 41.36% |
| TRV GP III, LLC | 3,048,780 | $18,902,000 | 9.26% |
| Omega Fund Management, LLC | 1,059,930 | $6,572,000 | 1.39% |
| Alambic Investment Management, L.P. | 50,622 | $314,000 | 0.13% |
| Spark Investment Management LLC | 244,300 | $1,514,000 | 0.07% |
| ALGERT GLOBAL LLC | 14,182 | $88,000 | 0.05% |
| Redmile Group, LLC | 254,590 | $1,578,000 | 0.05% |
| Granahan Investment Management | 125,533 | $778,000 | 0.04% |
| GSA CAPITAL PARTNERS LLP | 38,602 | $239,000 | 0.02% |
| Frontier Wealth Management LLC | 27,099 | $168,000 | 0.02% |